DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel

Bayar E., Cevik M., Caker S., Cagatay P., SÜSLEYİCİ B.

CURRENT DRUG SAFETY, vol.16, no.3, pp.252-258, 2021 (ESCI, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.2174/1574886315666210106141936
  • Journal Name: CURRENT DRUG SAFETY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, PASCAL, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.252-258
  • Keywords: AML-12 hepatocytes, 3T3-L1 adipocytes, clopidogrel, cell culture, DNA damage, DNA fragmentation, FATTY-ACID OXIDATION, IN-VIVO, INSULIN-RESISTANCE, CYTOCHROME-P450 3A, ADIPOSE-TISSUE, COMET ASSAY, ANTIPLATELET, TICLOPIDINE, CELLS, METABOLISM
  • Marmara University Affiliated: Yes

Abstract

Background: Clopidogrel has been commonly prescribed as a selective P2Y(12) receptor antagonist to reduce heart attack and stroke risk. Nearly 10% of absorbed clopidogrel is metabolized to active forms by cytochrome P450 (CYP) enzymes in the liver and 90% to inactive clopidogrel carboxylate by esterases.